

Denis Mulleman

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/9139176/denis-mulleman-publications-by-year.pdf>

Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

69 papers	1,837 citations	24 h-index	41 g-index
84 ext. papers	2,217 ext. citations	6 avg, IF	4.32 L-index

#	Paper	IF	Citations
69	Therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal disease: a systematic literature review informing EULAR points to consider. <i>RMD Open</i> , 2022 , 8, e002216	5.9	1
68	Spine immobilization and neurological outcome in Vertebral Osteomyelitis. SPONDIMMO, a prospective multicentric cohort.. <i>Joint Bone Spine</i> , 2021 , 105333	2.9	0
67	The Influence of Underlying Disease on Rituximab Pharmacokinetics May be Explained by Target-Mediated Drug Disposition. <i>Clinical Pharmacokinetics</i> , 2021 , 1	6.2	0
66	Predictors of response to TNF inhibitors in rheumatoid arthritis: an individual patient data pooled analysis of randomised controlled trials. <i>RMD Open</i> , 2021 , 7,	5.9	1
65	Large increase of vertebral osteomyelitis in France: a 2010-2019 cross-sectional study. <i>Epidemiology and Infection</i> , 2021 , 149, e227	4.3	3
64	Insuffisance de la mesure de densitométrie osseuse après fracture de l'avant-bras chez les femmes âgées de 50 ans ou plus: utilisation des bases de données de l'assurance maladie de la Région Centre Val de Loire. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2021 , 89, 99-99	0.1	
63	Poor assessment of bone mineral density after a forearm fracture in women aged 50 years or older: Data from a French health insurance database. <i>Joint Bone Spine</i> , 2021 , 88, 105121	2.9	
62	Machine learning reveals the most important psychological and social variables predicting the differential diagnosis of rheumatic and musculoskeletal diseases. <i>Rheumatology International</i> , 2021 , 1	3.6	1
61	A Comparative Study of Fibromyalgia, Rheumatoid Arthritis, Spondyloarthritis, and Sjögren's Syndrome; Impact of the Disease on Quality of Life, Psychological Adjustment, and Use of Coping Strategies. <i>Pain Medicine</i> , 2021 , 22, 372-381	2.8	16
60	Infliximab Treatment Does Not Lead to Full TNF- α Inhibition: A Target-Mediated Drug Disposition Model. <i>Clinical Pharmacokinetics</i> , 2021 , 1	6.2	1
59	High prevalence of clinical and biological features of metabolic syndrome in patients with epidural lipomatosis: A single-center, retrospective study. <i>Joint Bone Spine</i> , 2021 , 89, 105271	2.9	
58	Methotrexate effect on immunogenicity and long-term maintenance of adalimumab in axial spondyloarthritis: a multicentric randomised trial. <i>RMD Open</i> , 2020 , 6,	5.9	21
57	Exposure-Response Relationship of Certolizumab Pegol and Achievement of Low Disease Activity and Remission in Patients With Rheumatoid Arthritis. <i>Clinical and Translational Science</i> , 2020 , 13, 743-754	4.9	2
56	Increased high molecular weight adiponectin and lean mass during tocilizumab treatment in patients with rheumatoid arthritis: a 12-month multicentre study. <i>Arthritis Research and Therapy</i> , 2020 , 22, 224	5.7	11
55	2020 French recommendations on the management of septic arthritis in an adult native joint. <i>Joint Bone Spine</i> , 2020 , 87, 538-547	2.9	15
54	Recommandations françaises 2020 sur la prise en charge des arthrites septiques sur articulation native de l'adulte. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2020 , 87, 428-438	0.1	4
53	Non-Linear Rituximab Pharmacokinetics and Complex Relationship between Rituximab Concentrations and Anti-Neutrophil Cytoplasmic Antibodies (ANCA) in ANCA-Associated Vasculitis: The RAVE Trial Revisited. <i>Clinical Pharmacokinetics</i> , 2020 , 59, 519-530	6.2	5

52	CD4+ count-dependent concentration-effect relationship of rituximab in rheumatoid arthritis. <i>British Journal of Clinical Pharmacology</i> , 2019 , 85, 2747-2758	3.8	8
51	Model-Based Therapeutic Drug Monitoring of Infliximab Using a Single Serum Trough Concentration. <i>Clinical Pharmacokinetics</i> , 2018 , 57, 1173-1184	6.2	10
50	Comparison of the Big Five personality traits in fibromyalgia and other rheumatic diseases. <i>Joint Bone Spine</i> , 2017 , 84, 203-207	2.9	29
49	Antigenic burden and serum IgG concentrations influence rituximab pharmacokinetics in rheumatoid arthritis patients. <i>British Journal of Clinical Pharmacology</i> , 2017 , 83, 1773-1781	3.8	23
48	Biopharmaceuticals: Reference Products and Biosimilars to Treat Inflammatory Diseases. <i>Therapeutic Drug Monitoring</i> , 2017 , 39, 308-315	3.2	7
47	International and multidisciplinary expert recommendations for the use of biologics in systemic lupus erythematosus. <i>Autoimmunity Reviews</i> , 2017 , 16, 650-657	13.6	19
46	Current Practice for Therapeutic Drug Monitoring of Biopharmaceuticals in Spondyloarthritis. <i>Therapeutic Drug Monitoring</i> , 2017 , 39, 360-363	3.2	7
45	Rationale for Therapeutic Drug Monitoring of Biopharmaceuticals in Inflammatory Diseases. <i>Therapeutic Drug Monitoring</i> , 2017 , 39, 339-343	3.2	9
44	Therapeutic Drug Monitoring of Biopharmaceuticals May Benefit From Pharmacokinetic and Pharmacokinetic-Pharmacodynamic Modeling. <i>Therapeutic Drug Monitoring</i> , 2017 , 39, 322-326	3.2	18
43	Current Practices for Therapeutic Drug Monitoring of Biopharmaceuticals in Pediatrics. <i>Therapeutic Drug Monitoring</i> , 2017 , 39, 370-378	3.2	5
42	Current Practice for Therapeutic Drug Monitoring of Biopharmaceuticals in Rheumatoid Arthritis. <i>Therapeutic Drug Monitoring</i> , 2017 , 39, 364-369	3.2	16
41	Brief Report: Relationship Between Serum Infliximab Concentrations and Risk of Infections in Patients Treated for Spondyloarthritis. <i>Arthritis and Rheumatology</i> , 2017 , 69, 108-113	9.5	18
40	Practical recommendations for the use of therapeutic drug monitoring of biopharmaceuticals in inflammatory diseases. <i>Clinical Pharmacology: Advances and Applications</i> , 2017 , 9, 101-111	1.5	21
39	IgG1 Allotypes Influence the Pharmacokinetics of Therapeutic Monoclonal Antibodies through FcRn Binding. <i>Journal of Immunology</i> , 2016 , 196, 607-13	5.3	41
38	Impact of Anti-Inflammatory Drugs on Pyogenic Vertebral Osteomyelitis: A Prospective Cohort Study. <i>International Journal of Rheumatology</i> , 2016 , 2016, 9345467	2	1
37	Repeated decrease of CD4+ T-cell counts in patients with rheumatoid arthritis over multiple cycles of rituximab treatment. <i>Arthritis Research and Therapy</i> , 2016 , 18, 253	5.7	26
36	The underlying inflammatory chronic disease influences infliximab pharmacokinetics. <i>MAbs</i> , 2016 , 8, 1407-1416	6.6	37
35	Clinical Pharmacokinetics and Pharmacodynamics of Monoclonal Antibodies Approved to Treat Rheumatoid Arthritis. <i>Clinical Pharmacokinetics</i> , 2015 , 54, 1107-23	6.2	72

34	Suivi thérapeutique pharmacologique des anti-TNF- α au cours des spondyloarthrites. <i>Revue Du Rhumatisme Monographies</i> , 2015 , 82, 63-67	0	1
33	Development and validation of an enzyme-linked immunosorbent assay to measure adalimumab concentration. <i>Bioanalysis</i> , 2015 , 7, 1253-60	2.1	12
32	F-18 fluorodeoxyglucose positron emission tomography can detect early response to adalimumab, a tumor necrosis factor- α antagonist, in rheumatoid arthritis: A prospective pilot study. <i>Joint Bone Spine</i> , 2015 , 82, 381-3	2.9	4
31	Pharmacokinetics and concentration-effect relationship of adalimumab in rheumatoid arthritis. <i>British Journal of Clinical Pharmacology</i> , 2015 , 79, 286-97	3.8	51
30	Management of osteoporosis in women after forearm fracture: data from a French health insurance database. <i>Joint Bone Spine</i> , 2015 , 82, 52-5	2.9	10
29	Antibiotic treatment for 6 weeks versus 12 weeks in patients with pyogenic vertebral osteomyelitis: an open-label, non-inferiority, randomised, controlled trial. <i>Lancet, The</i> , 2015 , 385, 875-82 ⁴⁰		222
28	Towards an individualised target concentration of adalimumab in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 1428-9	2.4	21
27	Translational research in immune and inflammatory diseases; what are the challenges, expected advances, and innovative therapies?. <i>Therapie</i> , 2014 , 69, 291-302	3.8	
26	Relationship between inflammation and infliximab pharmacokinetics in rheumatoid arthritis. <i>British Journal of Clinical Pharmacology</i> , 2014 , 78, 118-28	3.8	57
25	Doit-on mesurer les concentrations sériques d'anti-TNF- α et/ou d'anticorps anti-médicament au cours de la polyarthrite rhumatoïde?. <i>Revue Du Rhumatisme (Edition Française)</i> , 2012 , 79, 97-100	0.1	
24	Early effect of hyaluronic acid intra-articular injections on serum and urine biomarkers in patients with knee osteoarthritis: An open-label observational prospective study. <i>Journal of Orthopaedic Research</i> , 2012 , 30, 679-85	3.8	34
23	Influence of methotrexate on infliximab pharmacokinetics and pharmacodynamics in ankylosing spondylitis. <i>British Journal of Clinical Pharmacology</i> , 2012 , 73, 55-65	3.8	40
22	Infliximab in ankylosing spondylitis: alone or in combination with methotrexate? A pharmacokinetic comparative study. <i>Arthritis Research and Therapy</i> , 2011 , 13, R82	5.7	31
21	Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases. <i>Arthritis Research and Therapy</i> , 2011 , 13, R105	5.7	109
20	Therapeutic drug monitoring of infliximab in spondyloarthritis: an observational open-label study. <i>Therapeutic Drug Monitoring</i> , 2011 , 33, 411-6	3.2	23
19	Pourquoi et comment optimiser l'utilisation des agents anti-TNF dans le traitement des spondylarthrites?. <i>Revue Du Rhumatisme (Edition Française)</i> , 2011 , 78, 201-203	0.1	
18	Trough infliximab concentration may predict long-term maintenance of infliximab in ankylosing spondylitis. <i>Scandinavian Journal of Rheumatology</i> , 2010 , 39, 97-8	1.9	11
17	Trough infliximab concentrations predict efficacy and sustained control of disease activity in rheumatoid arthritis. <i>Therapeutic Drug Monitoring</i> , 2010 , 32, 232-6	3.2	51

16	Infliximab for treating axial spondylarthropathy in everyday practice. <i>Joint Bone Spine</i> , 2009 , 76, 39-43	2.9	5
15	Effect of hyaluronic acid in symptomatic hip osteoarthritis: a multicenter, randomized, placebo-controlled trial. <i>Arthritis and Rheumatism</i> , 2009 , 60, 824-30		86
14	Primary neuroendocrine tumor of the sacrum: case report and review of the literature. <i>Skeletal Radiology</i> , 2009 , 38, 819-23	2.7	15
13	Evaluation of two strategies (initial methotrexate monotherapy vs its combination with adalimumab) in management of early active rheumatoid arthritis: data from the GUEPARD trial. <i>Rheumatology</i> , 2009 , 48, 1429-34	3.9	79
12	Infliximab concentration monitoring improves the control of disease activity in rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2009 , 11, R178	5.7	50
11	Can sciatica induced by disc herniation be treated with tumor necrosis factor alpha blockade?. <i>Arthritis and Rheumatism</i> , 2007 , 56, 3887-95		23
10	Percutaneous laser disc decompression for the treatment of lumbar disc herniation: a review. <i>Seminars in Arthritis and Rheumatism</i> , 2007 , 37, 20-30	5.3	32
9	Pathophysiology of disk-related sciatica. I.--Evidence supporting a chemical component. <i>Joint Bone Spine</i> , 2006 , 73, 151-8	2.9	133
8	Pathophysiology of disk-related low back pain and sciatica. II. Evidence supporting treatment with TNF-alpha antagonists. <i>Joint Bone Spine</i> , 2006 , 73, 270-7	2.9	31
7	Characteristics of patients with spinal tuberculosis in a French teaching hospital. <i>Joint Bone Spine</i> , 2006 , 73, 424-7	2.9	41
6	Medical mystery: extensive ecchymosis--the answer. <i>New England Journal of Medicine</i> , 2006 , 354, 419-20	59.2	2
5	An enzyme-linked immunosorbent assay for therapeutic drug monitoring of infliximab. <i>Therapeutic Drug Monitoring</i> , 2006 , 28, 169-74	3.2	86
4	Is epidural lipomatosis associated with abnormality of body fat distribution? A case report. <i>European Spine Journal</i> , 2006 , 15, 105-8	2.7	30
3	Images in clinical medicine. A medical mystery--extensive ecchymosis. <i>New England Journal of Medicine</i> , 2005 , 353, 2384	59.2	2
2	Multiple myeloma presenting with widespread osteosclerotic lesions. <i>Joint Bone Spine</i> , 2004 , 71, 79-83	2.9	15
1	Primary amyloidoma of the axis and acute spinal cord compression: a case report. <i>European Spine Journal</i> , 2004 , 13, 244-8	2.7	17